Both CLA and PPARγ agonist lead to a significant decrease of the VEGF isoforms and NOSII, thus indicating that even in glioblastoma  PPARγ is able to inhibit the angiogenic pathways [90]. This evidence concerns the gene PPARG and glioblastoma.